{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:01:53Z","timestamp":1792476113856,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science Foundation Ireland","award":["lifETIME CDT 18\/EPSRC-CDT\/3583"],"award-info":[{"award-number":["lifETIME CDT 18\/EPSRC-CDT\/3583"]}]},{"name":"Science Foundation Ireland","award":["lifETIME CDT 18\/EPSRC-CDT\/3583"],"award-info":[{"award-number":["lifETIME CDT 18\/EPSRC-CDT\/3583"]}]},{"DOI":"10.13039\/501100025294","name":"Research Ireland","doi-asserted-by":"crossref","award":["13\/RC\/2073_P2 Government of Ireland Postgraduate Scholarship-GOI (GOI"],"award-info":[{"award-number":["13\/RC\/2073_P2 Government of Ireland Postgraduate Scholarship-GOI (GOI"]}],"id":[{"id":"10.13039\/501100025294","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019905","name":"Galway University Foundation","doi-asserted-by":"publisher","award":["RGF023"],"award-info":[{"award-number":["RGF023"]}],"id":[{"id":"10.13039\/501100019905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51273-9","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:13:43Z","timestamp":1780031623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neurodegenerative and inflammatory biomarkers are detectable in saliva in multiple sclerosis"],"prefix":"10.1038","volume":"16","author":[{"given":"B.","family":"Castelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shapoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. P.","family":"Bocanegra-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Moosavizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Counihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Una","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"51273_CR1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028936","author":"H Lassmann","year":"2018","unstructured":"Lassmann, H. Multiple Sclerosis Pathology. Cold Spring Harb Perspect. Med. https:\/\/doi.org\/10.1101\/cshperspect.a028936 (2018).","journal-title":"Cold Spring Harb Perspect. Med."},{"key":"51273_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7861\/clinmed.2020-0292","volume":"20","author":"H Ford","year":"2020","unstructured":"Ford, H. Clinical presentation and diagnosis of multiple sclerosis. Clin. Med. 20, 380\u2013383. https:\/\/doi.org\/10.7861\/clinmed.2020-0292 (2020).","journal-title":"Clin. Med."},{"key":"51273_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241266180","author":"L Prosperini","year":"2024","unstructured":"Prosperini, L. et al. Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context. Mult Scler. https:\/\/doi.org\/10.1177\/13524585241266180 (2024).","journal-title":"Mult Scler."},{"key":"51273_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ana.26913","volume":"96","author":"M Calabrese","year":"2024","unstructured":"Calabrese, M. et al. Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis. Ann. Neurol. 96, 1\u201320. https:\/\/doi.org\/10.1002\/ana.26913 (2024).","journal-title":"Ann. Neurol."},{"key":"51273_CR5","doi-asserted-by":"publisher","first-page":"117471","DOI":"10.1016\/j.cca.2023.117471","volume":"548","author":"J Maroto-Garc\u00eda","year":"2023","unstructured":"Maroto-Garc\u00eda, J. et al. Biochemical biomarkers for multiple sclerosis. Clin. Chim. Acta Int. J. Clin. Chem. 548, 117471\u2013117471. https:\/\/doi.org\/10.1016\/j.cca.2023.117471 (2023).","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"51273_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101009","author":"M Di Filippo","year":"2024","unstructured":"Di Filippo, M. et al. Fluid biomarkers in multiple sclerosis: from current to future applications. Lancet Reg. Health - Eur. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101009 (2024).","journal-title":"Lancet Reg. Health - Eur."},{"key":"51273_CR7","doi-asserted-by":"publisher","first-page":"105035","DOI":"10.1016\/j.neubiorev.2023.105035","volume":"146","author":"TD Rademacher","year":"2023","unstructured":"Rademacher, T. D. et al. Molecular biomarkers and cognitive impairment in multiple sclerosis: State of the field, limitations, and future direction \u2013 A systematic review and meta-analysis. Neurosci. Biobehav Rev. 146, 105035\u2013105035. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105035 (2023).","journal-title":"Neurosci. Biobehav Rev."},{"key":"51273_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.0017","author":"AH Cross","year":"2024","unstructured":"Cross, A. H. et al. Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0017 (2024).","journal-title":"JAMA Neurol."},{"key":"51273_CR9","doi-asserted-by":"publisher","unstructured":"Paul, A. et al. Biomarkers in Multiple Sclerosis. Cold Spring Harb Perspect. Med. 9 https:\/\/doi.org\/10.1101\/cshperspect.a029058 (2019).","DOI":"10.1101\/cshperspect.a029058"},{"key":"51273_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00737-7","author":"M Levraut","year":"2025","unstructured":"Levraut, M. et al. The Kappa Free Light Chains Index and Central Vein Sign: Two New Biomarkers for Multiple Sclerosis Diagnosis. Neurol. Ther. https:\/\/doi.org\/10.1007\/s40120-025-00737-7 (2025).","journal-title":"Neurol. Ther."},{"key":"51273_CR11","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.curtheres.2024.100737","volume":"100","author":"S Thakur","year":"2024","unstructured":"Thakur, S. et al. Biomarkers of Hepatic Toxicity: An Overview. Curr. Ther. Res. Clin. Exp. 100, 100737. https:\/\/doi.org\/10.1016\/j.curtheres.2024.100737 (2024).","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"51273_CR12","doi-asserted-by":"publisher","first-page":"102339","DOI":"10.1016\/j.msard.2020.102339","volume":"44","author":"I Lotan","year":"2020","unstructured":"Lotan, I. et al. Saliva immunoglobulin free light chain analysis for monitoring disease activity and response to treatment in multiple sclerosis. Mult Scler. Relat. Disord. 44, 102339. https:\/\/doi.org\/10.1016\/j.msard.2020.102339 (2020).","journal-title":"Mult Scler. Relat. Disord"},{"key":"51273_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/cei.13086","volume":"192","author":"B Kaplan","year":"2018","unstructured":"Kaplan, B. et al. Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis. Clin. Exp. Immunol. 192, 7\u201317. https:\/\/doi.org\/10.1111\/cei.13086 (2018).","journal-title":"Clin. Exp. Immunol."},{"key":"51273_CR14","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/brain\/awn217","volume":"131","author":"L Piccio","year":"2008","unstructured":"Piccio, L. et al. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain 131, 3081\u20133091. https:\/\/doi.org\/10.1093\/brain\/awn217 (2008).","journal-title":"Brain"},{"key":"51273_CR15","first-page":"205521732110197","volume":"7","author":"ZA Ioannides","year":"2021","unstructured":"Ioannides, Z. A. et al. Correlations between macrophage\/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis. Mult Scler. J. - Exp. Transl Clin. 7, 20552173211019772 (2021).","journal-title":"Mult Scler. J. - Exp. Transl Clin."},{"key":"51273_CR16","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1177\/1352458512473362","volume":"19","author":"E Alvarez","year":"2013","unstructured":"Alvarez, E. et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler. J. 19, 1204\u20131208. https:\/\/doi.org\/10.1177\/1352458512473362 (2013).","journal-title":"Mult Scler. J."},{"key":"51273_CR17","doi-asserted-by":"publisher","first-page":"e1164","DOI":"10.1212\/NXI.0000000000001164","volume":"9","author":"S Floro","year":"2022","unstructured":"Floro, S. et al. Role of Chitinase 3\u2013like 1 as a Biomarker in Multiple Sclerosis. Neurol. Neuroimmunol. Neuroinflammation. 9, e1164. https:\/\/doi.org\/10.1212\/NXI.0000000000001164 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"51273_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto, G. et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857\u2013870. https:\/\/doi.org\/10.1002\/ana.24954 (2017).","journal-title":"Ann. Neurol."},{"key":"51273_CR19","doi-asserted-by":"publisher","first-page":"104854","DOI":"10.1016\/j.msard.2023.104854","volume":"77","author":"CG Ammitzb\u00f8ll","year":"2023","unstructured":"Ammitzb\u00f8ll, C. G. et al. NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis. Mult Scler. Relat. Disord. 77, 104854\u2013104854. https:\/\/doi.org\/10.1016\/j.msard.2023.104854 (2023).","journal-title":"Mult Scler. Relat. Disord"},{"key":"51273_CR20","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1177\/1352458519845844","volume":"26","author":"C Leurs","year":"2020","unstructured":"Leurs, C. et al. Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Mult Scler. Houndmills Basingstoke Engl. 26, 912\u2013923. https:\/\/doi.org\/10.1177\/1352458519845844 (2020).","journal-title":"Mult Scler. Houndmills Basingstoke Engl."},{"key":"51273_CR21","doi-asserted-by":"publisher","first-page":"e200049","DOI":"10.1212\/NXI.0000000000200049","volume":"10","author":"M Levraut","year":"2023","unstructured":"Levraut, M. et al. Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis. Neurol. Neuroimmunol. Neuroinflammation. 10, e200049. https:\/\/doi.org\/10.1212\/NXI.0000000000200049 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"issue":"7","key":"51273_CR22","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1373\/clinchem.2010.143529","volume":"56","author":"CM de Kat Angelino","year":"2010","unstructured":"de Kat Angelino, C. M., Raymakers, R., Teunesen, M. A., Jacobs, J. F. & Klasen, I. S. Overestimation of serum kappa free light chain concentration by immunonephelometry. Clin. Chem. 56 (7), 1188\u20131190. https:\/\/doi.org\/10.1373\/clinchem.2010.143529 (2010).","journal-title":"Clin. Chem."},{"issue":"Pt 3","key":"51273_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0004563214553808","volume":"52","author":"G Di Noto","year":"2015","unstructured":"Di Noto, G. et al. Polyclonal versus monoclonal immunoglobulin-free light chains quantification. Ann. Clin. Biochem. 52 (Pt 3), 327\u2013336. https:\/\/doi.org\/10.1177\/0004563214553808 (2015).","journal-title":"Ann. Clin. Biochem."},{"issue":"19\u201320","key":"51273_CR24","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.cca.2011.06.021","volume":"412","author":"M Vercammen","year":"2011","unstructured":"Vercammen, M., Meirlaen, P., Broodtaerts, L., Vande Broek, I. & Bossuyt, X. Effect of sample dilution on serum free light chain concentration by immunonephelometric assay. Clin. Chim. Acta. 412 (19\u201320), 1798\u20131804. https:\/\/doi.org\/10.1016\/j.cca.2011.06.021 (2011).","journal-title":"Clin. Chim. Acta"},{"issue":"10","key":"51273_CR25","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1515\/CCLM.2010.283","volume":"48","author":"M Bosmann","year":"2010","unstructured":"Bosmann, M. et al. Detection of serum free light chains: the problem with antigen excess. Clin. Chem. Lab. Med. 48 (10), 1419\u20131422. https:\/\/doi.org\/10.1515\/CCLM.2010.283 (2010).","journal-title":"Clin. Chem. Lab. Med."},{"key":"51273_CR26","doi-asserted-by":"publisher","unstructured":"Napodano, C. et al. Chapter Six - Mono\/polyclonal free light chains as challenging biomarkers for immunological abnormalities. In: (ed Makowski, G. S.) Advances in Clinical Chemistry. Elsevier, pp. 155\u2013209. https:\/\/doi.org\/10.1016\/bs.acc.2021.08.002","DOI":"10.1016\/bs.acc.2021.08.002"},{"key":"51273_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1212\/WNL.0000000000002832","volume":"87","author":"P de Flon","year":"2016","unstructured":"de Flon, P. et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology 87, 141\u2013147. https:\/\/doi.org\/10.1212\/WNL.0000000000002832 (2016).","journal-title":"Neurology"},{"key":"51273_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/1352458516639384","volume":"23","author":"L Novakova","year":"2017","unstructured":"Novakova, L. et al. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler. J. 23, 62\u201371. https:\/\/doi.org\/10.1177\/1352458516639384 (2017).","journal-title":"Mult Scler. J."},{"key":"51273_CR29","doi-asserted-by":"publisher","unstructured":"Kusnierova, P. et al. Neurofilament heavy chain and chitinase 3-like 1 as markers for monitoring therapeutic response in multiple sclerosis. Mult Scler. Relat. Disord. 91. https:\/\/doi.org\/10.1016\/j.msard.2024.105915 (2024).","DOI":"10.1016\/j.msard.2024.105915"},{"key":"51273_CR30","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1177\/13524585231188625","volume":"29","author":"MH Wessels","year":"2023","unstructured":"Wessels, M. H. et al. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light. Mult Scler. Houndmills Basingstoke Engl. 29, 1229\u20131239. https:\/\/doi.org\/10.1177\/13524585231188625 (2023).","journal-title":"Mult Scler. Houndmills Basingstoke Engl."},{"key":"51273_CR31","doi-asserted-by":"publisher","first-page":"e200050","DOI":"10.1136\/jnnp-2023-332251","volume":"10","author":"N Fissolo","year":"2023","unstructured":"Fissolo, N. et al. Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis. Neurol. Neuroimmunol. Neuroinflammation. 10, e200050. https:\/\/doi.org\/10.1136\/jnnp-2023-332251 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"51273_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jneuroim.2016.12.006","volume":"303","author":"C Matute-Blanch","year":"2017","unstructured":"Matute-Blanch, C. et al. Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. J. Neuroimmunol. 303, 62\u201365. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.12.006 (2017).","journal-title":"J. Neuroimmunol."},{"key":"51273_CR33","doi-asserted-by":"publisher","first-page":"10923","DOI":"10.1038\/s41598-020-67934-2","volume":"10","author":"X Ayrignac","year":"2020","unstructured":"Ayrignac, X. et al. Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity. Sci. Rep. 10, 10923. https:\/\/doi.org\/10.1038\/s41598-020-67934-2 (2020).","journal-title":"Sci. Rep."},{"key":"51273_CR34","doi-asserted-by":"publisher","unstructured":"Abdelhak, A. et al. Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker? Front Neurol; 10. Epub ahead of print 26 March 2019. https:\/\/doi.org\/10.3389\/fneur.2019.00280","DOI":"10.3389\/fneur.2019.00280"},{"key":"51273_CR35","doi-asserted-by":"publisher","unstructured":"Castillo-Villalba, J. et al. High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis. Front Immunol; 13. Epub ahead of print 7 March 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.827738","DOI":"10.3389\/fimmu.2022.827738"},{"key":"51273_CR36","doi-asserted-by":"publisher","unstructured":"Koerbel, K. et al. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis. Mult Scler. Relat. Disord. 87. https:\/\/doi.org\/10.1016\/j.msard.2024.105644 (2024).","DOI":"10.1016\/j.msard.2024.105644"},{"key":"51273_CR37","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s40263-021-00842-9","volume":"35","author":"M Biolato","year":"2021","unstructured":"Biolato, M. et al. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. CNS Drugs. 35, 861\u2013880. https:\/\/doi.org\/10.1007\/s40263-021-00842-9 (2021).","journal-title":"CNS Drugs"},{"key":"51273_CR38","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3390\/ijms24010852","volume":"24","author":"L Meunier","year":"2023","unstructured":"Meunier, L. & Larrey, D. Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility. Int. J. Mol. Sci. 24, 852. https:\/\/doi.org\/10.3390\/ijms24010852 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"51273_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.msard.2019.01.043","volume":"30","author":"C Solaro","year":"2019","unstructured":"Solaro, C. et al. Clinical correlates of 9-hole peg test in a large population of people with multiple sclerosis. Mult Scler. Relat. Disord. 30, 1\u20138. https:\/\/doi.org\/10.1016\/j.msard.2019.01.043 (2019).","journal-title":"Mult Scler. Relat. Disord"},{"key":"51273_CR40","doi-asserted-by":"publisher","first-page":"104970","DOI":"10.1016\/j.ebiom.2024.104970","volume":"101","author":"MS Freedman","year":"2024","unstructured":"Freedman, M. S. et al. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine 101, 104970. https:\/\/doi.org\/10.1016\/j.ebiom.2024.104970 (2024).","journal-title":"EBioMedicine"},{"key":"51273_CR41","doi-asserted-by":"publisher","unstructured":"La Civita, E. et al. Advancing Clinical Use of Neurofilament Light Chain: Translational Insights From Research to Routine Practice. Biomark. Insights. 20 https:\/\/doi.org\/10.1177\/11772719251364018 (2025).","DOI":"10.1177\/11772719251364018"},{"key":"51273_CR42","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s00415-025-13093-1","volume":"272","author":"MS Freedman","year":"2025","unstructured":"Freedman, M. S. et al. The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review. J. Neurol. 272, 400. https:\/\/doi.org\/10.1007\/s00415-025-13093-1 (2025).","journal-title":"J. Neurol."},{"key":"51273_CR43","doi-asserted-by":"publisher","unstructured":"Freedman, M. S. et al. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management, eBioMedicine, 101, 104970 https:\/\/doi.org\/10.1016\/j.ebiom.2024.104970","DOI":"10.1016\/j.ebiom.2024.104970"},{"key":"51273_CR44","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2025-1480","author":"EAJ Willemse","year":"2025","unstructured":"Willemse, E. A. J. et al. Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls. Clin. Chem. Lab. Med. (CCLM). https:\/\/doi.org\/10.1515\/cclm-2025-1480 (2025).","journal-title":"Clin. Chem. Lab. Med. (CCLM)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51273-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51273-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51273-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:03:29Z","timestamp":1786359809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51273-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51273"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51273-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}},{"value":"Ethical approval for this study was granted by the University of Galway Research Ethics Committee (Application number: 2022.02.004) and University Hospital Galway Ethics Committee (Application number: CA3272). All patients gave written consent before participating in the study.","order":2,"name":"Ethics","label":"Ethics and Patient Consent","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}}],"article-number":"24572"}}